Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CAF-derived PAI-1 serves as an EGFR ligand and fuels KRAS-mutant pancreatic cancer.

Nature communications - 4 Jul 2026

Wang Yu, Liu Chao, Gao Song, Wang Bo, Wang Hongwei, Shi Zijian, Xia Shunjin, Li Jiayong, Yao Xiaofeng, Guo Xiaofan, Zheng Jianwei, Zhou Qianqian, Chen Zhiqiang, Zheng Lei, Zhang Qiang, Du Jiang, Zhou Tianxing, Zhang Zhaoyu, Song Weijie, Qi Lisha, Wang Yalei, Sher Yuh-Pyng, Li Min, Zhou Xuan, Hung Mien-Chie, Ren Yu, Hao Jihui

Abstract excerpt

Epidermal growth factor receptor (EGFR) activation contributes to pancreatic cancer etiology, yet anti-EGFR therapy offers minimal clinical benefits in patients with KRAS mutations. We report that plasminogen activator inhibitor-1 (PAI-1) derived from cancer-associated fibroblasts (CAFs) is selectively elevated in KRAS-mutant tumors and functions as a ligand of EGFR, contributing to resistance to anti-EGFR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-Associated Fibroblasts
Share to Carcinoma, Pancreatic Ductal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ligands

Share to NF-kappa B

Share to Pancreatic Neoplasms

Share to Plasminogen Activator Inhibitor 1

Share to Proto-Oncogene Proteins p21(ras)

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 42401551
DOI: 10.1038/s41467-026-75132-3
PMCID: PMC13469601

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CAF-derived PAI-1 serves as an EGFR ligand and fuels KRAS-mutant pancreatic cancer.PMID 42401551Read ↗

Plasminogen activator inhibitors orchestrate the immunosuppressive tumor microenvironment in pancreatic cancerSemantic proximity Read ↗

The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding.Semantic proximity Read ↗

Extrinsic KRAS signaling shapes the pancreatic microenvironment through fibroblast reprogrammingSemantic proximity Read ↗

BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signalingSemantic proximity Read ↗

AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer.Semantic proximity Read ↗

Pancreatic stellate cells activated by mutant KRAS-mediated PAI-1 upregulation foster pancreatic cancer progression via IL-8.Semantic proximity Read ↗

Extravascular coagulation stabilizes pro-fibrotic stromal states via tumor-intrinsic PAR1 signaling in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Extrinsic KRAS Signaling Shapes the Pancreatic Microenvironment Through Fibroblast ReprogrammingSemantic proximity Read ↗

Acidic fibroblast growth factor underlies microenvironmental regulation of MYC in pancreatic cancerSemantic proximity Read ↗

SERPINE1 as a critical CAF-associated gene promotes myCAF phenotype activation and exosome-mediated gastric cancer progressionSemantic proximity Read ↗

Inactivation of Cancer-Associated-Fibroblasts Disrupts Oncogenic Signaling in Pancreatic Cancer Cells and Promotes Its Regression.Semantic proximity Read ↗

KRAS drives immune evasion in a genetic model of pancreatic cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.